Blood components and transfusion safety in acute myeloid leukemia (AML): Clinical outcomes and implications for practice in public blood centers
DOI:
https://doi.org/10.33448/rsd-v15i2.50590Keywords:
Transfusion Safety, Acute Myeloid Leukemia, Blood Component Transfusion, Blood Transfusion Service, Clinical Study.Abstract
Acute Myeloid Leukemia (AML) is an aggressive hematological neoplasm characterized by the clonal expansion of myeloid precursors with blockage of cell differentiation, culminating in the progressive replacement of normal hematopoiesis. In this sense, AML is configured as an onco-hematological emergency, increasing the demand for transfusion support. This study aimed to address transfusion safety in public services, including appropriate clinical indication, quality of blood components, and effective hemovigilance systems, contributing to an effective prognosis due to progressive transfusion dependence. Fourteen studies met the eligibility criteria. Given the clinical complexity of acute myeloid leukemia, it is becoming increasingly evident that transfusion management cannot be understood as a linear sequence of events, but as an integrated system of interactions between the biology of the disease, therapeutic strategies, the risks associated with transfusion, and clinical and systemic outcomes. Contemporary studies highlight that decisions related to blood component transfusion simultaneously influence the viability of antineoplastic treatment, the occurrence of adverse events, and the efficiency of health systems, especially in high-demand public settings such as large blood centers. It is concluded that transfusion, in this context, ceases to be an isolated technical act and becomes a high-impact clinical decision, capable of modifying therapeutic trajectories, outcomes, and costs. Strengthening safe, integrated, and evidence-based transfusion practices is not only a technical requirement but also an ethical and organizational imperative for public blood centers and health systems that aspire to offer excellent onco-hematological care.
References
Andreu, G., et al. (2025). Platelet additive solutions and pathogen reduction: Impact on clinical performance, consumption, and transfusion requirements. Transfus Med Revista. 39(1):150875. doi: 10.1016/j.tmrv.2025.150875.
Arber, D. A., Orazi, A., Hasserjian, R. P., et al. (2022). International Consensus Classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood, 140(11), 1200–1228.
Brasil. Agência Nacional de Vigilância Sanitária. (2022). Instrução Normativa nº 196, de 25 de novembro de 2022: Diretrizes e procedimentos para abordagem dos eventos adversos do ciclo do sangue no âmbito do Sistema Nacional de Hemovigilância. ANVISA.
Byun, J. M., et al. (2023). A pilot randomized study for optimal red cell transfusion in acute myeloid leukemia. Blood Transfus. 21(6):479-87. doi: 10.2450/BloodTransfus.482.
Carson, J. L., Stanworth, S. J., et al. (2021). Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database of Systematic Reviews. Cochrane Database Syst Rev. 12(12):CD002042. doi: 10.1002/14651858.CD002042.pub5.
Deschmann, E., et al. (2024). Clinical practice guideline for red blood cell transfusion: Evidence synthesis and guideline. JAMA Network Open. JAMA Netw Open. 7(6):e2417431. doi: 10.1001/jamanetworkopen.2024.17431.
Döhner, H., Wei, A. H., Appelbaum, F. R., et al. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 140(12), 1345–1377.
Estcourt, L. J., et al. (2015). Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015(11):CD010983. doi: 10.1002/14651858.CD010983.pub2.
Galvão, T. F., et al. (2022). A declaração PRISMA 2020 em português. Epidemiologia e Serviços de Saúde. 31(2). doi:10.1590/SS2237-9622202200011.
García-Otálora, M. A., et al. (2025). Platelet component safety in the era of new advancements in bacterial screening and pathogen reduction. Vox Sang. 120(8):846-857. doi: 10.1111/vox.70053. Epub 2025 Jun 8.
Gil, A. C. (2017). Como elaborar um projeto de pesquisas. Editora Atlas.
Instituto Nacional de Câncer. (2023). Estimativa 2023: Incidência de câncer no Brasil (triênio 2023–2025). INCA.
Khoury, J. D., Solary, E., Abla, O., et al. (2022). Myeloid and histiocytic/dendritic neoplasms. Leukemia. 36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
Loghavi, S., et al. (2024). Fifth edition of the World Health Organization classification of hematolymphoid tumors: Myeloid neoplasms. Mod Pathol. 37(2):100397. doi: 10.1016/j.modpat.2023.100397. Epub 2023 Dec 1.
Morton, S., et al. (2022). Do liberal thresholds for red cell transfusion result in improved outcomes in acute myeloid leukemia? Haematologica. 107(6). https://doi.org/10.3324/haematol.2021.279867.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71.
Pereira et al. (2018). Metodologia da pesquisa científica. [Free ebook]. Editora da UFSM.
Rezvany, M. R., et al. (2024). Evaluation of bacterial safety approaches of platelet blood components: Bacterial screening versus pathogen reduction technologies. Frontiers in Medicine. Volume 11 - 2024 | https://doi.org/10.3389/fmed.2024.1325602.
Semple, J. W., et al. (2019). Transfusion-associated circulatory overload and transfusion-related acute lung injury: Diagnosis and clinical relevance. Blood. 133 (17): 1840–53.
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1).
Solves, P., et al. (2025). Patient Blood Management in hematology: Focusing on platelet transfusion practice and appropriateness. Journal of Clinical Medicine. 14(23). Doi: 10.3390/jcm14238434.
Stone, R. M., Mandrekar, S. J., Sanford, B. L., et al. (2017). Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. The New England Journal of Medicine, 377, 454–464.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Weber de Santana Teles, Max Cruz da Silva, Carlos Henrique Santiago Martins, Ádamo Newton Marinho Andrade, Fernanda Kelly Fraga Oliveira, Ana Paula Barreto Prata Silva, Douglas Abilio, Lorena Eugênia Rosa Coelho, Orleane Souza Rezende, Raphael Davisson Lopes Santos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
